

Nanocarrier Based Drug Delivery Of Biologics: Enabling The Rise Of Biosimilars In India



Akshay R. Yadav*, Dr. Shubhangi A. Patil, Dr. Niranjan D. Chivate

Department of Pharmaceutical Chemistry, KCT's Krishna College of Pharmacy, Karad,
Maharashtra, India-415539

Email: akshayyadav24197@gmail.com

Abstract

Biologics are redefining modern therapies but the clinical efficacy is hampered by bioavailability, stability and delivery issues. Nanocarrier based drug delivery presently shows new opportunities to optimize targeted drug delivery, immunogenicity and pharmacokinetics. In India, for enhancing treatment outcomes and to improve accessibility with clinical efficacy, researchers are integrating nanotechnology and biosimilars emerging transformative approaches. Advances in polymeric and inorganic and lipid based nanocarrier systems have remarkably improved the delivery of biologics by addressing challenges such as low bioavailability, targeted delivery and poor stability limitations. These advancements are making a strategic shift from conventional towards the high value biopharmaceutical. Further, they support cost-effective therapies options, promote innovation and strengthen India's competitiveness in the global pharmaceutical sector.

Keywords: Nanocarriers, Biosimilars, Biologics, Drug delivery, Indian Pharmaceutical Industry.

1. Introduction

The development of a novel drug delivery system for targeted distribution of biologics and increasing stability to enhance therapeutic outcomes results in paradigm shift in India's biosimilar sector (1). But there are some restrictions to their rapid approval by some regulatory agencies to launch in the market (2). This barrier is hampering market expansion

and limiting availability of inexpensive biosimilar choices for large patient populations (3). In drug delivery systems for selection of proper formulation are critical in disease like inflammatory bowel disease (IBD). So, Nanocarrier drug delivery is also not easy to remove legislative barriers to improve accessibility (4).

1.1 Overview of Biologics and Biosimilars

Biologics are specialized biological products prepared by using advancing technologies and transformed in a way for the health care system to receive therapy for autoimmune disease and different types of cancers (5). Copies of these biologics are referred to as biosimilars that entered the market for offering more affordable options for costly biologic drugs (6). To make sure biosimilars efficacy, safety and regulatory agencies such as FDA created approval rules with procedures that are difficult to understand (7). As the market impact of biosimilar is advantageous, by reducing cost and increasing patient access for effective therapy (8,9).

1.2 Need for Advanced Drug Delivery in India

In India, nanocarrier drug delivery is used to know a variety of health care concerns including a lack of access to effective medicines. Drug delivery facilitates the site specific drug release by improving bioavailability and reducing systemic side effects with increasing patient compliance. Advance technological breakthroughs may address the current health care situation (10).

2. Challenges in Delivery of Biologics

There are multiple challenges faced by delivery of biologics in formulation to remain stable. Key limitations in delivery of biologics include achieving highly selective targeting strategies without causing unintended damage to healthy cells along with navigating complex regulatory frameworks (11). Noncompliance by patients may also impact biologics effectiveness because educating patients related to important steps for treatment remains tough and the problem related with biologics (12).



Figure 1. Different challenges in drug delivery

2.1 Stability and Degradation Issues

The delivery of biologics in India faces challenges associated with degradation and stability. Most biologics are very sensitive to environmental conditions requiring strict temperature control throughout the supply chain. To maintain the cold chain from the point of manufacturing to final administration to patients makes it difficult due to increased risk of temperature control at multiple stages. Regulatory complexities related to importation and approval of biologics are limiting patient accessibility. Overcoming these challenges is important to ensure equitable and improved access to advanced healthcare in the Indian population (13).

2.2 Poor Bioavailability and Targeting Limitations

In disease conditions the targeting of biologics and biosimilars with bioavailability continues to be a significant challenge (14). Rheumatoid arthritis and Inflammatory diseases require prompt treatment but due to bioavailability of currently available biologics is often insufficient to achieve optimal therapeutic level. Additionally, issues associated with infliximab along with challenges in targeting strategies can adversely affect both safety and effectiveness of biologic therapies (15).

Table 1. Comparative disadvantage of Bioavailability, distribution and targeting efficiency

Aspect	Biologics	Biosimilars	Key Limitation
Bioavailability	Low oral bioavailability due to large molecular size and enzymatic degradation	Similar limitations as reference biologics (protein instability and degradation)	Requires parenteral administration (IV/SC) (16)
Permeability & Distribution	Poor membrane permeability and limited tissue penetration	Comparable distribution challenges due to structural similarity	Inefficient delivery to intracellular or specific tissue targets (16)
Targeting Efficiency	Limited site-specific targeting; relies on passive distribution or antibody binding	Emerging targeting strategies but still under development	Need for advanced delivery systems (nanocarriers, active targeting) (17)

3. Development of Biologics and biosimilars by Nanocarrier based drug delivery strategies

Nanocarriers may be used for targeting and distributing biologics and biosimilars for improving their safety and efficacy (18).




Figure 2. Integrated Strategy for Nanocarrier-Based Enhancement of Biologic and Biosimilar Therapeutics

Nanocarriers may help to lower the side effects and enhance therapeutic effectiveness. They are more feasible to target oral delivery of the biologics orally by overcoming challenges related with absorption and stability (19,20).

3.1 Nanocarrier Systems for Enhanced Delivery of Biologics

Nanocarrier and intracellular delivery of biologic drugs like peptides, proteins and monoclonal antibodies has shown interest in the field of drug delivery (21,22). Many attempts have been made to overcome challenges like biosafety and instability concerns to achieve oral administration of drugs (23,24).

3.2 Recent Advances and Case Studies in Nanocarrier enabled Biosimilars

Recent advances in nanocarrier delivery have enhanced targeted delivery of drugs used for enhancing the safety & efficacy in biosimilars. As they are changing clinical practice with patient expectations in a number of therapeutics disciplines, this article explains how nanocarriers enhance targeted drug delivery for disease sites. Nano emulsions are the best examples of nanocarriers to enhance delivery of drugs to the disease sites and show potential in treatment of diseases such as IBD. As biosimilars show new outcomes in treatment of

illness linked to abnormal immune response, testing, production and regulatory issues need to be resolved. The different approaches have been researched and present obstacles and potential paths for applications of nano based drug delivery for treatment of IBD. Personalized medicine in which treatments are made for specific illnesses and made possible by smart nanocarriers may enhance the focus of the delivery of medicine to disease areas and rapid evolution of biologics and biosimilars in clinical practices and patient expectations (25).

4. Indian Scenario and Opportunities

India's market for biologics and biosimilar offers tremendous development potential. The demand for reasonable biologic substitutes for expanding healthcare demands a nation with an enormous population. The biopharmaceutical areas are also facing a number of difficulties and remain competitive to endure over the long run, and this area urgently needs to paradigm (26,27). Regulatory environment of nation are becoming easily favourable for the biosimilar approval with large number of approvals have occurred recently and India might potentially adopt some techniques to develop biosimilars to keep an eye on global landscape, As technology continues to advance the Indian market may expand rapidly (28,29)

Table 2. Indian Scenario and opportunities for biosimilars drugs

Aspect	Current Scenario in India	Opportunities	Challenges	Key Insight
Market Landscape	Rapidly expanding biosimilars market with strong domestic companies	Entry into global regulated markets	Pricing pressure and competition	India is emerging as a global biosimilars (29)
Regulatory Framework	CDSCO and DBT guidelines support biosimilar approval	Scope for regulatory harmonization	Complex approval pathways	Strengthened regulations will improve trust (30)
Manufacturing & R&D	Cost-effective biologics production infrastructure	Investment in innovation and advanced delivery systems	High R&D costs and technical complexity	Strong potential for global manufacturing leadership (31)

Therapeutic & Export Potential	High demand in oncology, diabetes, autoimmune diseases	Expanding exports to US, EU, emerging markets	Stringent international compliance requirements	Enhances global access to affordable biologics (32)
--------------------------------	--	---	---	---

4.1 Growth of Biosimilars Market in India

Regulatory framework for quicker biosimilar certification supported by India quickly by expanding biosimilars market. Other elements driving the market expansion are the cost-effectiveness for biosimilars comparatively to innovative biologic drugs (33). The pharmaceutical industry with the competitive environment has shown more innovation and cost cutting measures for producing high quality biosimilars (34).

4.2 Nanotechnology in Enhancing Accessibility

Biologics and biosimilars are better prepared and delivered in healthcare areas for advancement in nanotechnology. Biosimilars are delivered and targeted by using small nanocarriers, which also offer defense against degradation of the environment. Nanotechnology simplifies the formulation and development while supporting regulatory pathways and enabling design innovation based nanocarrier systems for targeted drug delivery systems across different disease conditions (35,36).

5. Regulatory and Technological Challenges and future directions

In India regulatory frameworks for biologics and biosimilars face major challenges they need to be addressed including heterogeneity in present inadequate bioinformatics resources and biosimilar approval procedure and lack of standards with respect to biosimilar references and weak scientific approach for characterization with frequently antiquated manufacturing technologies. Market access and their growth felicitated by improving technology and regulatory frameworks (37).

6. Conclusion

Nanocarrier based drug delivery gives revolutionary solutions to different problems related with biologics and biosimilars and these systems increase therapeutic efficacy while lowering the side effects by enhancing bioavailability and targeted drug delivery and stability. The

integration can strengthen the biopharmaceutical industry in India and enable the production of affordable biosimilars. To fully realize the potential and positioning India as a global leader in the cutting edge in drug delivery technologies with respect to encouraging frameworks, sustained innovation and scalable manufacturing techniques would be essential.

7. References

1. Rishishwar S, Asokan N. Innovations in drug delivery systems for biologics: enhancing stability and targeted delivery for next-generation therapeutics. *Chin. J. Appl. Physiol.* 2025;41:e20250001.
2. Panda S, Singh PK, Mishra S, Mitra S, Pattnaik P, Adhikary SD, Mohapatra RK. Indian biosimilars and vaccines at crossroads—replicating the success of pharmacogenetics. *Vaccines.* 2023;11(1):110.
3. Farswan AS, Joshi S, Sanwal R, Dhsamana A. Biopharmaceuticals: A Review of Biopolymeric Drugs and Accessibility Challenges in India. *Journal of Polymer & Composites.* 2024;12(5): 32-28
4. Aljabri A, Soliman GM, Ramadan YN, Medhat MA, Hetta HF. Biosimilars versus biological therapy in inflammatory bowel disease: Challenges and targeting strategies using drug delivery systems. *Clinical and Experimental Medicine.* 2025;25(1):107.
5. Naser-Tavakolian A, Heard JR, Ahdoot M. Biologics. In: *Translational Urology.* Amsterdam: Academic Press; 2025. p. 355–360..
6. Mascarenhas-Melo F, Diaz M, Gonçalves MB, Vieira P, Bell V, Viana S, Nunes S, Paiva-Santos AC, Veiga F. An overview of biosimilars development, quality, regulatory issues, and management in healthcare. *Pharmaceuticals.* 2024;17(2):235.
7. Cosenza ME. Biologics. In: *An overview of FDA regulated products.* Amsterdam: Academic Press; 2025. p. 111–132.
8. Hariprasad SM, Gale RP, Weng CY, Rezk MF, Tadayoni R. An introduction to biosimilars for the treatment of retinal diseases: a narrative review. *Ophthalmology and Therapy.* 2022;11(3):118-129.
9. Klein K, Gencoglu M, Heisterberg J, Acha V, Stolk P. The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries: K. Klein et al. *BioDrugs.* 2023;37(2):235-45.
10. Dua K, Mehta M, Pinto TD, Pont LG, Williams KA, Rathbone M, editors. *Advanced drug delivery systems in the management of cancer.* Academic Press; 2021. p. 355–360..
11. Yu YB, Briggs KT, Taraban MB, Brinson RG, Marino JP. *Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics:* Yu et al. *Pharmaceutical Research.* 2021;38(1):3-7.
Sarkis M, Bernardi A, Shah N, Papathanasiou MM. Emerging challenges and opportunities in pharmaceutical manufacturing and distribution. *Processes.* 2021;9(3):457.
12. Sarvepalli S, Pasika SR, Verma V, Thumma A, Bolla S, Nukala PK, Butreddy A, Bolla PK. A review on the stability challenges of advanced biologic therapeutics. *Pharmaceutics.* 2025;17(5):550.
13. Akram MS, Pery N, Butler L, Shafiq MI, Batool N, Rehman MF, Grahame-Dunn LG, Yetisen AK. Challenges for biosimilars: focus on rheumatoid arthritis. *Critical reviews in biotechnology.* 2021;41(1):121-53.
14. Cheshomi M, Shobeiri N, Tajani AS, Khameneh B. Strategic approaches for overcoming peptide and protein drug limitations. *The Protein Journal.* 2026;45(1):8-21.
15. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. *Nat Rev Drug Discov.* 2014;13(9):655–672.
16. Aljabri A, Soliman GM, Ramadan YN, Medhat MA, Hetta HF. Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems. *Clin Exp Med.* 2025;25(1):107.
17. Cao Y, Rewatkar P, Wang R, Hasnain SZ, Popat A, Kumeria T. Nanocarriers for oral delivery of biologics: small carriers for big payloads. *Trends in pharmacological sciences.* 2021;42(11):957-72.
18. Mühlberg E, Burtscher M, Umstätter F, Fricker G, Mier W, Uhl P. Trends in liposomal nanocarrier strategies for the oral delivery of biologics. *Nanomedicine.* 2021;16(20):1813-32.
19. Dirisala A, Li J, Gonzalez-Carter D, Wang Z. Delivery systems in biologics-based therapeutics. *Frontiers in Bioengineering and Biotechnology.* 2023;11:1274210.
20. Zhu YF, He MQ, Lin CS, Ma WH, Ai Y, Wang J, Liang Q. Multifunctional nanocarrier drug delivery systems: from diverse design to precise biomedical applications. *Advanced Healthcare Materials.* 2026;15(2):e02178.
21. Hassan A, Zameer MD, Khan M, Hassan T, Umair M, Iqbal MN, Ahi MJ, Gul P, Ahmed N. Smart nanocarriers for biosimilars: a new frontier in targeted drug delivery. *J Drug Deliv Sci Technol.* 2026 Feb;116:107955.
22. Kalaw San Pascual JC, Kangsamaksin T. Biologics, Biosimilars, and Biobetters: Therapeutic Innovations Reshaping Modern Medicine. *Advanced Biology.* 2025;9(12):e00326.
23. Singh P, Desai PN, Dutta V. Rising biosimilars in the Indian biopharmaceutical industry: emerging challenges and way forward. *Technology Analysis & Strategic Management.* 2023;35(9):1145-60.

24. Rathod JA, Amthaniwala BK. Comparative insights into biosimilar development in the UAE and India: Opportunities, challenges, and global trends. *Indian Journal of Pharmacy and Pharmacology*. 2025;12(4):194–205
25. Sinha S, Raphael R. Developing Biosimilars: Challenges and Opportunities. *Pharmaceut Med*. 2025;39(5):341-352
26. Heise T, DeVries JH. Biosimilar insulins: Narrative review of the regulatory framework and registration studies. *Diabetes Obes Metab*. 2025;27 Suppl 5(Suppl 5):16-23.
27. Evan Kuilenburg ABP, Hollak CEM, Travella A, Jacobs M, Gentilini LD, Leen R, der Vlugt KMMG, Stet FSB, Goorden SMI, van der Veen S, Criscuolo M, Papouchado M. Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation. *Drugs R D*. 2023;23(2):141-153.
28. Ascef BO, Almeida MO, Medeiros-Ribeiro AC, Oliveira de Andrade DC, Oliveira Junior HA, de Soárez PC. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2023;6(5):e2315872.
29. Gandhi S, Patankar D, Kashiramka S, Rathore AS. The economics of translating a biosimilar from lab to market in India. *Annals of the New York Academy of Sciences*. 2024;1541(1):219-29.
30. BS AK, PM H. A Review on Emerging Trends in Biologic Drugs and Biosimilars. *Plant Biotechnology Persa*. 2025;7(3):58-67
31. Nikitina V, Laurini GS, Montanaro N, Motola D. Comparative Safety Profiles of Biosimilars vs. Originators Used in Rheumatology: A Pharmacovigilance Analysis of the EudraVigilance Database. *J Clin Med*. 2025;14(5):1644.
32. Bas TG. Innovative formulation strategies for biosimilars: trends focused on buffer-free systems, safety, regulatory alignment, and intellectual property challenges. *Pharmaceuticals*. 2025;18(6):908.
33. Rizwan A, Dubey K, Malhotra V, Bhatnagar S. Biosimilars: Bridging the Gap in Biologics, Access, and Affordability. *Journal of Pharmaceutical and BioTech Industry*. 2026;3(1):2.
34. Kaur S, Yadav S, Sahu V, Sharma N, Shukla VK. Biosimilar regulations: Current framework and future prospects. *Current Drug Safety*. 2025 May 23.
35. Singh P, Desai PN, Dutta V. Rising biosimilars in the Indian biopharmaceutical industry: emerging challenges and way forward. *Technol Anal Strateg Manag*. 2021;35(1):1-17
36. Wei K, Kou Y, Kan H, He W, Li J, Guo X. Biosimilars: navigating the regulatory maze across two worlds. *Trends Biotechnol*. 2023;41(7):847-850.
37. Joshi D, Khursheed R, Gupta S, Wadhwa D, Singh TG, Sharma S, Porwal S, Gauniyal S, Vishwas S, Goyal S, Gupta G, Eri RD, Williams KA, Dua K, Singh SK. Biosimilars in Oncology: Latest Trends and Regulatory Status. *Pharmaceutics*. 2022 ;14(12):2721.